“Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s141. doi:10.25251/skin.7.supp.141.